Cargando…

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

Despite the application of conventional therapies, the prognosis of advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer therapy. Emerging evidence support the feasibility of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhening, Xie, Tong, Zhang, Xiaotian, Qi, Changsong, Shen, Lin, Peng, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369180/ https://www.ncbi.nlm.nih.gov/pubmed/32694895 http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.02

Ejemplares similares

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
por: Zhang, Zhening, et al.
Publicado: (2022)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023)

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
por: Xie, Tong, et al.
Publicado: (2021)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET‐amplified gastric cancer
por: Zhang, Zhening, et al.
Publicado: (2023)

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
por: Kundel, Yulia, et al.
Publicado: (2020)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
por: Businello, Gianluca, et al.
Publicado: (2022)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
por: Bai, Rilan, et al.
Publicado: (2020)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
por: Gronnier, Caroline
Publicado: (2022)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
por: Karim, Frederic, et al.
Publicado: (2023)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein–Barr Virus Associated Gastric Cancer: A Retrospective Study
por: Xie, Tong, et al.
Publicado: (2021)

Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date
por: Wheelden, Megan, et al.
Publicado: (2020)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Seesaha, Poshita-Kumari, et al.
Publicado: (2021)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction
por: Ko, Seung Yeon, et al.
Publicado: (2014)

Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors—Comparison Against a Therapy Naïve Cohort
por: Schoop, Hauke, et al.
Publicado: (2019)

Minimally invasive surgery for gastro-oesophageal junction adenocarcinoma: Current evidence and future perspectives
por: Bîrlă, Rodica, et al.
Publicado: (2023)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Photodynamic therapy in combination with immune checkpoint inhibitors plus chemotherapy for first-line treatment in advanced or metastatic gastric or gastroesophageal junction cancer: A phase 2–3 clinical trial protocol
por: Yu, Yang, et al.
Publicado: (2023)

Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
por: Mehta, Rutika, et al.
Publicado: (2018)

Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review
por: Mukherjee, Sarbajit, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
por: Sammarco, Enrico, et al.
Publicado: (2023)

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
por: Chen, Li-Tzong, et al.
Publicado: (2017)

Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
por: Paszt, Attila, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gsckt3rtps7asdjaqjdn3gllod